Updated:
NeoLight
NeoLight is a Scottsdale-based medical device company focused on the newborn care market.
NeoLight
NeoLight is a Scottsdale-based medical device company focused on the newborn care market. The firm's product line includes the Skylife Neonatal Phototherapy System for jaundice treatment, the nëo CFM with aEEG for brain monitoring, the ICON Ophthalmic Imaging System for retinal screening, and the P.A.L. device for non-nutritive sucking development. These devices are designed for hospital neonatal intensive care units and pediatric practices. No publicly available information details the firm's ownership structure, funding history, or investment strategy. The company does not disclose AUM, deployment figures, or institutional investors. Its products target neonatal conditions including jaundice, brain monitoring, and feeding development, but specific portfolio companies or clinical partners are not named in its public materials. The firm's website describes a high-performance executive team but lists no individual names or titles. The company maintains a support and sales operation reachable via email and phone, but no additional offices are disclosed. No recent operational events, such as funding rounds, clinical trials, or regulatory approvals, are publicly verifiable within the last two years. NeoLight's structural differentiator is its claim to "empathy-driven" product design, which it says places the doctor-nurse-mother-infant ecosystem at the center. Without disclosed financials, team size, or funding sources, however, the firm remains opaque relative to typical venture-backed or family-office-held medical device companies.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Scottsdale
Corporate office
Scottsdale, AZ, United States
Sector focus
Frequently asked questions
Who runs investment decisions at NeoLight?
NeoLight's website describes a high-performance executive team but does not name any individual members. No publicly available sources identify a CEO, CIO, or managing principal by name. The firm's ownership and capital structure remain undisclosed.
Is NeoLight structured as a family office or a medical device company?
NeoLight presents itself as a medical device manufacturer, not as a family office or investment vehicle. Its public materials focus entirely on its neonatal product lines and clinical support. No financial or investment management function is mentioned publicly.
What investment stages does NeoLight target?
NeoLight does not disclose any investment activity. The firm's public profile is limited to product development and sales of its neonatal devices. There is no evidence of venture-stage, growth-stage, or direct investment participation.
What products does NeoLight offer for neonatal care?
NeoLight's product portfolio includes the Skylife Neonatal Phototherapy System for jaundice, the nëo CFM with aEEG for brain monitoring, the ICON Ophthalmic Imaging System for retinal screening, and the P.A.L. device for non-nutritive sucking development. These are marketed to hospital NICUs and pediatric practices.
Does NeoLight maintain philanthropic structures or operating companies?
No public information indicates that NeoLight operates a philanthropic foundation or separate operating entities beyond its core medical device business. The company's website does not reference any charitable arm or related vehicles.
Where does NeoLight's underlying wealth come from?
NeoLight does not disclose its ownership or source of capital. The firm's public materials do not identify any family office, private equity sponsor, or individual founder backing. Wealth origin is unknown.
What geographic markets does NeoLight serve?
NeoLight is headquartered in Scottsdale, Arizona, and its contact page supports product orders and technical support for customers in the United States. The company does not publicly list distributors or clinical partners in other regions, so its international reach is unclear.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: